Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop.NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fon…
Capricor Therapeutics, Inc. (CAPR), LKQ Corp. (LKQ), and Paramount Skydance Corp. (PSKY) stocks touched 52-week lows on Thursday as regulatory concerns, operational disruptions, and legal uncertainty each weighed heavily on investors’ sentiment.Capricor stock plunged 36% and is on track for its wor…
Capricor Therapeutics is facing a pivotal FDA advisory committee meeting on Wednesday for deramiocel, its experimental cell therapy aimed at Duchenne muscular dystrophy (DMD), a rare and devastating muscle-wasting disease in children.Earlier this week, the agency questioned how Capricor analyzed re…
Capricor publishes final one-year HOPE-3 Phase 3 results in The Lancet and reports an updated LVEF statistical model that changes significance for the key secondary endpoint.Key Highlights:Original SEC Filing: CAPRICOR THERAPEUTICS, INC. [ CAPR ] - 8-K - Jul. 29, 2026This is an AI-powered summary…
--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings----Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Primary Endpoint, with Deramiocel Slowing Upper Limb Function Decline by 54 Percent versus Placebo (PUL…
Capricor Therapeutics (CAPR) remained in the spotlight on Tuesday, as Wall Street continued to react to the U.S. Food and Drug Administration’s briefing documents on the firm’s Duchenne muscular dystrophy therapy, with Alliance Global Partners slashing its price target on the stock by 86%.At the ti…
U.S. futures declined in the overnight session late Monday as a heavy sell-off in semiconductor stocks weighed on the indexes, especially the Nasdaq.Meanwhile, cooling geopolitical tensions led to a decline in oil prices at the start of Big Tech earnings week as markets look to earnings from four “…
Capricor Therapeutics (CAPR) saw its shares tumble roughly 65% on Monday after the U.S. Food and Drug Administration released briefing documents for an upcoming Advisory Committee meeting to evaluate the company's application seeking approval for its drug Deramiocel.The Cellular, Tissue, and Gene T…
Shares of Capricor Therapeutics (CAPR) tanked more than 67% on Monday after U.S. Food and Drug Administration (FDA) reviewers expressed concerns in briefing documents over whether its lead therapy Deramiocel has shown sufficient effectiveness to treat cardiomyopathy in patients with Duchenne muscul…
With Outlook Therapeutics’ LYTENAVA winning the U.S. Food and Drug Administration’s green light on Friday, the spotlight shifts to a fresh slate of high-stakes regulatory showdowns.The days ahead pack several binary or near-binary catalysts for U.S. biotech and biopharma companies—decisions that co…
Shares of Capricor Therapeutics (CAPR) were in focus in pre-market trading on Wednesday as investors looked ahead to the U.S. Food and Drug Administration’s (FDA) upcoming Advisory Committee meeting for the company's investigational Duchenne muscular dystrophy (DMD) therapy, Deramiocel. The regulat…
Shares of Capricor Therapeutics (CAPR) closed at a four-month low on Monday after new filings showed that senior executives sold nearly $1.5 million in shares, while the company prepares for a key FDA review of its Duchenne muscular dystrophy treatment.CAPR stock slumped 10% on Monday to end at $23…
Krasney Karen, an officer serving as EVP, General Counsel, sold 24,100 shares of common stock under a Rule 10b5-1 trading plan at a weighted average price of $30.38 per share, with individual sale prices ranging from $30.00 to $30.88, for total proceeds of $732,158, and after the sale she directly…
Capricor Therapeutics announced an FDA advisory committee meeting on July 29, 2026 to review its BLA for Deramiocel, with a PDUFA target action date of August 22, 2026.Key Highlights:Original SEC Filing: CAPRICOR THERAPEUTICS, INC. [ CAPR ] - 8-K - Jun. 26, 2026This is an AI-powered summary. It may…
